CLV IntelligenceReimbursement Policy Monitoring

Code intelligence

FDA-NDA208026 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code FDA-NDA208026.

Elevated code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Elevated
0

Critical

0%

1

High

100%

0

Routine

0%

0

Low

0%

New this month

+1

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: JENTADUETO XR (LINAGLIPTIN AND METFORMIN HYDROCHLORIDE) — Type 4 - New Combination

Policy FDA-NDA208026 · Endocrinology

High

Jentadueto XR is an oral extended-release tablet combining linagliptin (a DPP-4 inhibitor) and metformin hydrochloride, approved for type 2 diabetes management. As an oral combination product, it foll

View alert

Audit documentation

Building an audit file that includes FDA-NDA208026?

The Tripwire Audit Pack exports 12 months of Endocrinology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Endocrinology audit pack — $349One-time purchase · not a subscription